The funding will support the ATTC Network for an additional four years. Credit: Cell and Gene Therapy Catapult.

The UK’s National Institute for Health and Care Research (NIHR) has announced a £17.9m ($22.7m) investment in the Advanced Therapy Treatment Centre Network (ATTC Network) to enhance the UK’s clinical trial infrastructure.

This initiative aims to enhance the country’s environment for advanced therapy medicinal product (ATMP) clinical trials.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The funding will support the ATTC Network for a further four years and will be overseen by Innovate UK, with Cell and Gene Therapy Catapult (CGT Catapult) coordinating the ATTC Network.

ATMPs are therapeutics such as gene therapies, cell therapies and tissue-engineered products.

The ATTC Network presently comprises Innovate Manchester Advanced Therapy Centre Hub, Midlands-Wales Advanced Therapy Treatment Centre and the Northern Alliance Advanced Therapies Treatment Centre.

See Also:

The UK’s prominence in ATMP clinical research is significant, hosting 175 ongoing trials and accounting for 9% of ATMP trials worldwide.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With many more products in the development pipeline, there is a pressing need to ensure that the UK National Health Service (NHS) can deliver these advanced therapies to patients across the UK on a larger scale.

The latest funding will build on the existing work of the ATTC network, in conjunction with NIHR infrastructure and devolved equivalents, to improve clinical trial readiness.

This collaborative effort is intended to solidify the UK’s global appeal as a destination for clinical research in the field of advanced therapies.

Backed by the UK Department of Health and Social Care, the NIHR funds, enables and delivers health and social care research.

UK Health Minister Andrew Stephenson said: “This investment reaffirms the UK’s position as a global leader in clinical research.

“It will help roll out revolutionary medical products more quickly, potentially treating the root cause of disorders and diseases such as Alzheimer’s and cancer.

“Harnessing technological and digital innovations is one of our primary focuses under the first ever NHS Long Term Workforce Plan, enabling new and advanced ways of working.”